Zhang Dai-Min, Chen Shaoliang
Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China.
Cardiol Res Pract. 2020 Oct 25;2020:8104939. doi: 10.1155/2020/8104939. eCollection 2020.
Coronary heart disease is a major cause of death and disability in developed countries. Stent implantation has become an efficacious treatment for a culprit lesion vessel of the coronary artery. However, 10%-20% restenosis is still an important complication that restricts the clinical safety and efficacy of drug-eluting stents. In-stent restenosis may lead to the recurrence of major cardiovascular adverse events, including angina pectoris, acute myocardial infarction, and even sudden cardiac death. These events are currently serious problems that occur after coronary stent implantation. Clinical physicians face a difficult choice for in-stent restenosis treatment. Recent studies indicate that a drug-coated balloon has promising clinical efficacy similar to the drug-eluting stents for treating coronary in-stent restenosis. Therefore, in this study, we highlight the progress of coronary intervention and the use of drug-coated balloons in the treatment of in-stent restenosis (ISR).
冠心病是发达国家死亡和残疾的主要原因。支架植入已成为治疗冠状动脉罪犯病变血管的有效方法。然而,10%-20%的再狭窄仍然是一个重要的并发症,限制了药物洗脱支架的临床安全性和有效性。支架内再狭窄可能导致主要心血管不良事件的复发,包括心绞痛、急性心肌梗死,甚至心源性猝死。这些事件是目前冠状动脉支架植入后出现的严重问题。临床医生在支架内再狭窄治疗上面临艰难的选择。最近的研究表明,药物涂层球囊在治疗冠状动脉支架内再狭窄方面具有与药物洗脱支架相似的、有前景的临床疗效。因此,在本研究中,我们重点介绍冠状动脉介入治疗的进展以及药物涂层球囊在支架内再狭窄(ISR)治疗中的应用。